

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**September 19, 2023  
Date of Report (date of earliest event reported)**

**Asensus Surgical, Inc.  
(Exact name of Registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction of incorporation or  
organization)**

**0-19437  
(Commission  
File Number)**

**11-2962080  
(I.R.S. Employer  
Identification Number)**

**1 TW Alexander Drive, Suite 160  
Durham, NC 27703  
(Address of principal executive offices)  
919-765-8400  
(Registrant's telephone number, including area code)**

**Not Applicable  
(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading symbol</b>	<b>Name of each exchange on which registered</b>
<b>Common Stock \$0.001 par value per share</b>	<b>ASXC</b>	<b>NYSE American</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

On July 14, 2023, Asensus Surgical, Inc., a Delaware corporation (the “Company”) announced that a leading United States-based hospital had entered into a lease of the Company’s Senhance® Surgery System for use in pediatric surgery. The hospital is Mayo Clinic Hospital, Saint Marys Campus. The Senhance System has been installed and the first pediatric cases using the Senhance System have occurred at Mayo Clinic Hospital, Saint Marys Campus.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ASENSUS SURGICAL, INC.**

Date: September 19, 2023

/s/ Shameze Rampertab

Shameze Rampertab

Executive Vice President and Chief Financial Officer